Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Odevixibat in Patients With Alagille Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Genetically confirmed diagnosis of Alagille syndrome~* History of significant pruritus as measured by the Albireo Observer or Patient Reported Outcome instrument~* Elevated serum bile acid level~Key Exclusion Criteria:~* History or ongoing presence of other types of liver disease (eg. biliary atresia, progressive familial intrahepatic cholestasis, hepatocellular carcinoma)~* History of liver transplant, or a liver transplant is planned within 6 months of randomization~* ALT \>10× upper limit of normal (ULN) at screening~* Total bilirubin \>15 × ULN at screening~* Patient suffers from uncontrolled, recalcitrant pruritic condition other than Alagille syndrome

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Odevixibat (A4250) (Type: EXPERIMENTAL): Capsules for oral administration once daily for 24 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Capsules for oral administration (to match active) once daily for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).